Home  »  Market Insights   »  23andMe Holding Co. (ME) Stock Rapidly Rising in A...

23andMe Holding Co. (ME) Stock Rapidly Rising in Aftermarket, Here’s the reason

23andMe Holding Co. (ME), a consumer genetics and research company, has soared 12.31% in aftermarket trading session. As a result, ME stock is trading at $8.85 at the time of this writing. The increase has come after ME was mentioned on CNBC by Eric Jackson. On Thursday, ME stock declined 0.88% during regular trading hours and closed the day at $7.88.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The reason behind the ME surge

Eric Jackson of EMJ Capital appeared on CNBC on Thursday. According to him, the people are misinterpreting ME. For him, he said, it was more of a pre-stage therapeutics company as well as a subscription service. He said that potentially, ME could be worth as much as GSK ten years from now on. After his comments, ME stock is continuously soaring in after-market trading session.  

Conversation of ME CEO

On 24th September, CEO of ME Anne Wojcicki joined the popular interview show “Influencers with Andy Serwer” to discuss the politicization of medicine during these harsh times of pandemic. According to him, the consumerization of the healthcare industry has provided the companies like 23andMe Holding to provide their expertise in the medical industry, to have their say in policy matters, and to have more of a role in scientific leadership.

Q2 2021 financial highlights

On 13th August, ME reported the financial results for the first quarter of the fiscal year 2021 which ended on 30th June 2021. The total revenue generated by the company for the period stood at $59.23 million against $48.05 million for the same period of 2020. The cost of revenue for the period was $28.54 million against $25.56 million for the same period of 2020. The gross profit for the quarter was $30.69 million against $22.49 million for the same period of 2020. The total operating expenses for the period were $72.24 million against $59.21 million for the same period of 2020. The company suffered a loss of $41.55 million from the operations during the quarter against $36.72 million for the same period of 2020. The net loss for the period was $42.02 million against $35.77 million for the same period of 2020. The loss per basic and diluted share for the period was $0.25 against $0.38 for the same period of 2020. The company had cash and cash equivalents of $769.93 million on 30th June. The total assets were $947.01 million while total liabilities were $284.47 million.

What’s ahead for ME?

Statistics reveal that ME has declined more than 20% during the last 3 months. But with the improvement and expansion plans in its business, analysts are hopeful that ME tends to depict strong performance in near future.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam